Top Stories
The company said AI cut the pharmaceutical manufacturing batch-record review time by 89%, from nearly 26 hours to under three hours.
The two will combine molecular tumour profiling with existing clinical data to explore whether previously studied drugs could benefit different cancer populations.
Popular LLMs favoured products that appeared prominently in Google searches or had dedicated Wikipedia pages.
The machine learning models performed best at predicting the risk of lung, oesophageal and liver cancers.
A six-session app-based treatment could offer women with cancer an alternative to sleep medication, the long-term benefits of which remain uncertain.
Conference News
Humanitas Global Health debuts at the American Association of Pharmaceutical Scientists’ 2026 PharmSci 360 congressCompany hosts a panel discussion on translating artificial intelligence innovations i...
Exploratory analysis presented at the ESMO Congress suggests changes in lactate dehydrogenase (LDH) measurements over time may complement imaging in assessing disease activity in glioblastomaCHANHASSE...
Natera’s oncology portfolio featured in 25 ESMO abstracts including 9 oral presentations, with publications in Nature Medicine and ESMO OpenAUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA)...
Cambridge, UK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Patients Know Best (PKB), the UK patient-controlled health record platform, will exhibit at HLTH Las Vegas (15–18 November, The Venetian Expo) as part ...
DUBAI, UAE, Oct. 26, 2026 /PRNewswire/ -- The 31st International Society of Hypertension Scientific Meeting and 17th Emirates Cardiac Society Annual Conference (ISH-ECS 2026) took place in Dubai from ...
